Hemispherx Biopharma, Inc. (HEB)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
1.260.00 (0.00%)
At close: 4:00 PM EDT
People also watch:
GNBTCVMBCRXCTICVICL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.25
Prev Close1.26
Bid1.25 x 4500
Ask1.26 x 1100
Day's Range1.25 - 1.28
52wk Range0.72 - 2.64
1y Target EstN/A
Market Cap26.14M
P/E Ratio (ttm)-2.50
Beta-1.11
Volume24,658
Avg Vol (3m)163,679
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case

    PHILADELPHIA, Sept. 22, 2016-- Hemispherx Biopharma, announced today that the Court of Chancery of the State of Delaware has issued an order granting final approval of a settlement of the derivative and ...

  • GlobeNewswire11 days ago

    Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards

    PHILADELPHIA, Sept. 19, 2016-- Hemispherx Biopharma, announced today that, based on a notice received on September 15, 2016 from the New York Stock Exchange, Inc., the Company has regained compliance with ...

  • American City Business Journals24 days ago

    Philadelphia biotech firm expecting $5M from stock sale

    Hemispherx Biopharma Inc. has entered into definitive agreements with two health-care focused institutional investors for a direct stock offering expected to generate gross proceeds of $5 million. Philadelphia-based Hemispherx intends to use the net proceeds from the offering for preparation of technology transfer opportunities , expenses related to Ampligen manufacturing, and for other working capital and general corporate purposes. "What we've been doing, and what continues to be a priority, is reaching out to the industry to try and form partnerships for advancing Ampligen," said Thomas K. Equels, the CEO of Hemispherx.